This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Siemens Healthineers aims to speed up deliveries to customers with new “mega dep...
Opinion/decision on a Paediatric investigation plan (PIP): Feraccru, ferric malt...
Chris Gibson, Recursion’s head, cited the role small business grants played in h...
After Novartis and Roche grew their sales last year, the Swiss pharma giants are...
Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed ...
Bristol Myers Squibb has bolstered its case for Opdivo to be used as a pre-opera...
Tech adoption might slow down if the FDA layoffs shift responsibility for medica...
Human medicines European public assessment report (EPAR): Obgemsa, vibegron, Dat...
Human medicines European public assessment report (EPAR): Pluvicto, lutetium (17...
Human medicines European public assessment report (EPAR): Zoely, nomegestrol,est...
President Trump told reporters that tariffs on pharmaceuticals would start at "2...
The essential biotech news stories of the day, brought to you by The Readout.
Novartis has committed $7.5 million to an initiative aiming to save 100,000 live...
Recce Pharmaceuticals’ synthetic anti-infective gel successfully treated a range...
Human medicines European public assessment report (EPAR): Vevizye, ciclosporin, ...
The FDA has authorized ImmunityBio’s expanded access program to bring alternativ...
Human medicines European public assessment report (EPAR): Prevenar 20 (previousl...
Despite AstraZeneca’s revenue growing 18% in 2024, the pay package for CEO Pasca...
EMA workshop on the challenges in drug development, regulation and clinical prac...
Human medicines European public assessment report (EPAR): Pregabalin Sandoz, pre...
Finding clinical trials with the ACT EU Trial Map, Online, European Medicines Ag...
Human medicines European public assessment report (EPAR): Balversa, Erdafitinib,...